Espinosa FR, Pavía LAA

Idioma: Español
Referencias bibliográficas: 21
Paginas: 200-204
Archivo PDF: 51.14 Kb.

RESUMEN

Los bloqueadores de los receptores plaquetarios de las glicoproteínas IIb/IIIa han demostrado su utilidad en el tratamiento de los síndromes coronarios inestables. En este trabajo presentamos una revisión de los estudios multicéntricos más importantes que dan evidencia de la utilidad de estos medicamentos. Enunciamos la nueva alternativa en el tratamiento con la combinación de dosis bajas de fibrinolíticos y glicoproteínas IIb/IIIa, los cuales han logrado más posibilidades de reperfundir las coronarias epicárdicas y la microcirculación, y mayor rapidez en lograr flujo TIMI 3. Proponemos las indicaciones de estos medicamentos en las diferentes condiciones clínicas de los síndromes coronarios inestables.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemostat Thromb 1989; 9: 117.

2. The EPIC Investigators. Use of a monoclonal antibody directed against the platel glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Eng J Med 1994; 330: 956.

3. The EPILOG Investigators. Platel Glycoprotein IIb/IIa receptor blockade and low-dose heparin during percutaneous coronary revascularitzation. N Eng J Med 1997; 336: 1689.

4. Brener SJ, Barr LA, Burchenal JEB et al. On behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platel glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734.

5. Morris DC. Results from late-breaking clinical trials sessions at ACCIS ’99 and ACC ’99. American College of Cardiology. J Am Coll Cardiol 1999; 34: 1.

6. Stone GW. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Presented at 72nd Scientific Sessions of the American Heart Association, 1999.

7. The EPISTENT Investigators. Randomised placebo-controlled and ballon-angioplasty-controlled trial to assess safety of coronary stenting use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87.

8. Lincoff AM Calliff RM, Moliterno DJ et al. For the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319.

9. Topol EJ, Mark DB, Lincoff AM et al. Outcomes at 1 year and economics implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019.

10. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445.

11. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unestable Signs and Symptoms (PRIMS-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban inestable angina and non-Q wave myocardial infarction. N Eng J Med 1998; 338: 1488.

12. Szucs TD, Meyer BJ, Kiowski W. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting. An analysis based on the PRIMS PLUS trial. Eur Herat J 1999; 20: 1253.

13. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein GP IIb/IIIa with eptifibratide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436.

14. Kleiman NS, Lincoff AM, Flaker GC et al. Early percutaneous intervention, platelet inhibition with eptifibratide, and clinical outcomes in patients with acude coronary syndromes. Circulation 2000; 101: 751.

15. Ohman EM, Kleiman NS, Gacioch G et al. Combined accelerated tissue-plasminigen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997; 95: 846.

16. The IMPACT-II Investigators. Randomized placebo-controlled trial effect of eptifibratide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422.

17. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agent that block the platelel glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829.

18. Cannon CP. Overcoming thrombolytic resistance. Rationale and initial clinical experience combining thrombilytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1395.

19. Ferguson JJ, Meeting highlights. Highlights of the 71st Scientific Sessions of the American Heart Association. Circulation 1999; 100; 126.

20. Antman EM, Giugliano RP, Gibson MC et al. For the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis. Result of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99: 2720.

21. De Lemus JA, Antman EM, Gibson CM et al. Abciximab Improves Both Epicardical Flow and Myocardial Reperfusion in ST Elevation Myocardial Infarction. Observations from the TIMI 14 trial. Circulation 2000; 101: 239.